Apex Clinic Limited 15121724 false 2023-09-07 2024-09-30 2024-09-30 The principal activity of the company is that of locum services and other specialised health services. Digita Accounts Production Advanced 6.30.9574.0 true 15121724 2023-09-07 2024-09-30 15121724 2024-09-30 15121724 bus:OrdinaryShareClass1 2024-09-30 15121724 core:CurrentFinancialInstruments 2024-09-30 15121724 core:CurrentFinancialInstruments core:WithinOneYear 2024-09-30 15121724 core:FurnitureFittingsToolsEquipment 2024-09-30 15121724 bus:SmallEntities 2023-09-07 2024-09-30 15121724 bus:AuditExemptWithAccountantsReport 2023-09-07 2024-09-30 15121724 bus:FilletedAccounts 2023-09-07 2024-09-30 15121724 bus:SmallCompaniesRegimeForAccounts 2023-09-07 2024-09-30 15121724 bus:RegisteredOffice 2023-09-07 2024-09-30 15121724 bus:Director1 2023-09-07 2024-09-30 15121724 bus:OrdinaryShareClass1 2023-09-07 2024-09-30 15121724 bus:PrivateLimitedCompanyLtd 2023-09-07 2024-09-30 15121724 bus:Agent1 2023-09-07 2024-09-30 15121724 1 2023-09-07 2024-09-30 15121724 core:FurnitureFittingsToolsEquipment 2023-09-07 2024-09-30 15121724 core:UKTax 2023-09-07 2024-09-30 15121724 countries:EnglandWales 2023-09-07 2024-09-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 15121724 (England and Wales)

Apex Clinic Limited
(formerly Apex Locum Pharma Limited)

Unaudited Filleted Financial Statements

for the Period from 7 September 2023 to 30 September 2024

 

Apex Clinic Limited
(formerly Apex Locum Pharma Limited)

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 8

 

Apex Clinic Limited
(formerly Apex Locum Pharma Limited)

Company Information

Director

Miss Shivika Babbar

Registered office

39 Sutton Avenue
Langley
Slough
SL3 7AP

Accountants

Aventus Partners Limited
Chartered AccountantsHygeia Building
Ground Floor
66-68 College Road
Harrow
Middlesex
HA1 1BE

 

Apex Clinic Limited
(formerly Apex Locum Pharma Limited)

(Registration number: 15121724) (England and Wales)
Balance Sheet as at 30 September 2024

Note

2024
£

Fixed assets

 

Tangible assets

5

8,667

Current assets

 

Stocks

6

5,524

Debtors

7

6,874

Cash at bank and in hand

 

42,460

 

54,858

Creditors: Amounts falling due within one year

8

(19,427)

Net current assets

 

35,431

Net assets

 

44,098

Capital and reserves

 

Called up share capital

9

100

Retained earnings

43,998

Shareholders' funds

 

44,098

For the financial period ending 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476; and

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

The financial statements were approved and authorised for issue by the director on 17 April 2025
 

.........................................
Miss Shivika Babbar
Director

   
     
 

Apex Clinic Limited
(formerly Apex Locum Pharma Limited)

Notes to the Unaudited Financial Statements for the Period from 7 September 2023 to 30 September 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The company was formerly known as Apex Locum Pharma Limited.

The address of its registered office is:
39 Sutton Avenue
Langley
Slough
SL3 7AP
United Kingdom

These financial statements were authorised for issue by the director on 17 April 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The functional and presentational currency is GBP Sterling (£), being the currency of the primary economic environment in which the company operates in. The amounts are presented rounded to the nearest pound.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

Apex Clinic Limited
(formerly Apex Locum Pharma Limited)

Notes to the Unaudited Financial Statements for the Period from 7 September 2023 to 30 September 2024 (continued)

2

Accounting policies (continued)

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixtures, fittings and equipment

25% Reducing balance basis

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

 

Apex Clinic Limited
(formerly Apex Locum Pharma Limited)

Notes to the Unaudited Financial Statements for the Period from 7 September 2023 to 30 September 2024 (continued)

2

Accounting policies (continued)

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

 

Apex Clinic Limited
(formerly Apex Locum Pharma Limited)

Notes to the Unaudited Financial Statements for the Period from 7 September 2023 to 30 September 2024 (continued)

2

Accounting policies (continued)

Financial instruments

Classification
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties and loans from related parties.

 Recognition and measurement
Debt instruments (other than those wholly repayable or receivable within one year), including loans and other debtors and creditors, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method.

Debt instruments that are payable or receivable within one year, typically trade creditors or debtors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration, expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms of financed at a rate of interest that is not a market rate or in case of an out-right short term loan not at a market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.


 Impairment
Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss if recognised in the Profit and loss account.

For financial assets measured as amortised cost, the impairment loss is measured as the difference between an asset’s carrying amount and the present value of estimated cash flows discounted at the asset’s original effective interest rate. If a financial asset has a variable interest rate, the discounted rate for measuring any impairment loss is the current effective interest rate determined under the contract.

Financial assets and liabilities are offset and the net amount reported in the Balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

3

Staff numbers

The average monthly number of persons employed by the company (including the director) during the period, was 1.

4

Taxation

Tax charged/(credited) in the profit and loss account

2024
£

Current taxation

UK corporation tax

8,732

 

Apex Clinic Limited
(formerly Apex Locum Pharma Limited)

Notes to the Unaudited Financial Statements for the Period from 7 September 2023 to 30 September 2024 (continued)

5

Tangible assets

Furniture, fittings and equipment
 £

Cost

Additions

11,556

At 30 September 2024

11,556

Depreciation

Charge for the period

2,889

At 30 September 2024

2,889

Carrying amount

At 30 September 2024

8,667

6

Stocks

2024
£

Other inventories

5,524

7

Debtors

2024
£

Trade debtors

6,874

6,874

8

Creditors

Creditors: amounts falling due within one year

2024
£

Due within one year

Taxation and social security

8,732

Accruals and deferred income

1,200

Directors current account

9,495

19,427

 

Apex Clinic Limited
(formerly Apex Locum Pharma Limited)

Notes to the Unaudited Financial Statements for the Period from 7 September 2023 to 30 September 2024 (continued)

9

Share capital

Allotted, called up and fully paid shares

2024

No.

£

Ordinary shares of £1 each

100

100

   

10

Dividends

2024

£

Interim dividend of £15.00 per ordinary share

1,500